GLP-1: Assay to Aggregates
Therapeutic peptides are a fast-growing pharmaceutical drug class, but they present unique analytical challenges due to closely related process impurities, degradation products, and higher-order aggregate species. This webinar shows how complementary chromatographic workflows can be used to address those challenges, with examples spanning assay, related substances, stability-indicating analysis, and aggregate assessment. Real-world applications will cover aggregation profiles of key GLP-1 receptor agonists, including semaglutide, liraglutide, and tirzepatide.
Key Learning Points
- Understand the main analytical challenges involved in therapeutic peptide characterization, including closely related impurities, degradation products, and aggregate species.
- Describe where reversed-phase chromatography and size exclusion chromatography fit across therapeutic peptide development workflows.
- Learn how different reversed-phase selectivities were used for semaglutide assay, related substances, and stability/degradant studies, and understand how similar workflows can be adapted for other GLP-1 analogs, including tirzepatide.
Who Should Attend
- Any liquid chromatography users working with, or interested in analyzing peptide therapeutics by HPLC.
Speaker: Sean Orlowicz (Principal Market Development Manager, Phenomenex)
Sean Orlowicz has been working in the field of analytical chemistry for over 23yrs. After receiving his degree in Chemistry from the University of Illinois at Chicago, he started his career in large scale synthesis, using HPLC and GC techniques in reaction monitoring and purification. Sean took this experience to Phenomenex in 2003, working on site with clients worldwide on method development, troubleshooting and method transfer. Sean explored instrumentation for a few years, growing to specialize in LCMS, before returning to Phenomenex to help build and manage Phenomenex’s new applications laboratory. Since then, Sean has been driving innovation and growth though Business Development efforts, and most recently, in 2025 Sean has taken a Market Development Management role, spearheading our global efforts in Pharmaceuticals.
